Tidal Investments LLC Acquires 362 Shares of AstraZeneca PLC (NASDAQ:AZN)

Tidal Investments LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 5.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 6,649 shares of the company’s stock after purchasing an additional 362 shares during the quarter. Tidal Investments LLC’s holdings in AstraZeneca were worth $518,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of AZN. FMR LLC grew its stake in shares of AstraZeneca by 1.1% during the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock worth $1,801,080,000 after buying an additional 258,477 shares during the last quarter. Fisher Asset Management LLC grew its position in AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after acquiring an additional 524,175 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in AstraZeneca by 16.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after purchasing an additional 488,644 shares in the last quarter. Clearbridge Investments LLC raised its position in AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after purchasing an additional 186,010 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after purchasing an additional 1,605,758 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN opened at $65.35 on Monday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The firm’s fifty day simple moving average is $69.02 and its two-hundred day simple moving average is $76.28. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The stock has a market capitalization of $202.63 billion, a P/E ratio of 31.27, a price-to-earnings-growth ratio of 1.19 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the firm posted $0.87 earnings per share. The firm’s revenue was up 18.0% on a year-over-year basis. As a group, analysts predict that AstraZeneca PLC will post 4.11 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.